Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes

Hu,Zhi‑Juan; Ren,Lu‑Ping; Wang,Chao; Liu,Bing; Song,Guang‑Yao

doi:10.3892/etm.2014.1830

Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes

Authors:
- Zhi‑Juan Hu
- Lu‑Ping Ren
- Chao Wang
- Bing Liu
- Guang‑Yao Song
View Affiliations

Affiliations: Department of Nephrology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China
Published online on: July 7, 2014 https://doi.org/10.3892/etm.2014.1830
Pages: 951-956

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Microalbuminuria (MAU) is a strong predictor of diabetic nephropathy (DN), which is the main cause of morbidity and mortality in patients with diabetes mellitus (DM). Dyslipidemia exists in the majority of patients with DM and contributes to micro‑ and macrovascular complications associated with DM. Apolipoprotein CIII (apoCIII) is an inhibitor of the activity of lipoprotein lipase, which metabolizes triglyceride (TG) in very low‑density lipoprotein (VLDL) and facilitates its clearance from plasma. The aim of the present study was to investigate the associations between apoCIII and MAU and the effects of atorvastatin in type 2 diabetes. In total, 120 subjects were divided into type 2 diabetes and type 2 DN groups, while 60 healthy subjects were selected as controls. The patients with DN were administered 20 mg atorvastatin daily for 16 weeks. Blood pressure, body mass index (BMI) and levels of HbA1c, FBG, TG, VLDL‑cholesterol (VLDL‑C), apoCIII and MAU were markedly elevated in the type 2 diabetes and type 2 DN groups compared with those in the control group (P<0.01), while high‑density lipoprotein‑cholesterol (HDL‑C) levels were decreased significantly (P<0.01). All patients with type 2 DN showed significantly elevated blood pressure, apoCIII levels, MAU, course of the disease and rate of stroke and retinopathy compared with the patients with type 2 diabetes (P<0.01). MAU was significantly positively correlated with the course of the disease, systolic blood pressure, diastolic blood pressure, BMI and HbA1c, FBG, TG, total cholesterol, low‑density lipoprotein‑cholesterol, VLDL‑C and apoCIII levels (P<0.05), whereas negatively correlated with HDL‑C levels (r=‑0.194, P=0.020). Logistic regression analysis showed that apoCIII levels were independently associated with MAU (odds ratio, 1.100; 95% confidence interval, 1.037‑1.153; P<0.001). Atorvastatin improved the lipid profile and MAU in patients with type 2 DN (P<0.01). Therefore, the present study demonstrated that an independent positive correlation exists between the levels of apoCIII and MAU in patients with type 2 diabetes. Furthermore, atorvastatin may be used to improve the lipid profile and MAU in type 2 DN.

View Figures

View References

1	Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH and Steffes MW; American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 27(Suppl 1): S79–S83. 2004. View Article : Google Scholar
2	Ravid M, Brosh D, Ravid-Safran D, Levy Z and Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 158:998–1004. 1998. View Article : Google Scholar : PubMed/NCBI
3	Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 71:S22–S24. 1999. View Article : Google Scholar : PubMed/NCBI
4	Boyle KE, Phillips MC and Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta. 1430:302–312. 1999. View Article : Google Scholar : PubMed/NCBI
5	Breyer ED, Le NA, Li X, Martinson D and Brown WV: Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. J Lipid Res. 40:1875–1882. 1999.PubMed/NCBI
6	Jong MC, Hofker MH and Havekes LM: Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 19:472–484. 1999. View Article : Google Scholar : PubMed/NCBI
7	Campos H, Perlov D, Khoo C and Sacks FM: Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res. 42:1239–1249. 2001.PubMed/NCBI
8	Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C, Dahllöf B and Camejo G: A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res. 46:1999–2006. 2005. View Article : Google Scholar : PubMed/NCBI
9	Schonfeld G, George PK, Miller J, Reilly P and Witztum J: Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28:1001–1010. 1979. View Article : Google Scholar : PubMed/NCBI
10	Talmud PJ and Humphries SE: Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol. 8:154–158. 1997. View Article : Google Scholar : PubMed/NCBI
11	Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA and Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:1886–1892. 2000. View Article : Google Scholar : PubMed/NCBI
12	Lee SJ, Campos H, Moye LA and Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 23:853–858. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R and Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 78:1287–1295. 1986. View Article : Google Scholar : PubMed/NCBI
14	Ebara T, Ramakrishnan R, Steiner G and Shachter NS: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 99:2672–2681. 1997. View Article : Google Scholar : PubMed/NCBI
15	Sehayek E and Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 266:18259–18267. 1991.PubMed/NCBI
16	Jong MC, Hofker MH and Havekes LM: Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 19:472–484. 1999. View Article : Google Scholar : PubMed/NCBI
17	Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 12:297–304. 2001. View Article : Google Scholar : PubMed/NCBI
18	Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D and Brown WV: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 49:167–177. 2000. View Article : Google Scholar : PubMed/NCBI
19	Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:499–502. 1972.PubMed/NCBI
20	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
21	Genuth SM: The case for blood glucose control. Adv Intern Med. 40:573–623. 1995.PubMed/NCBI
22	Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 352:213–219. 1998. View Article : Google Scholar : PubMed/NCBI
23	Brunzell JD and Ayyobi AF: Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 115(Suppl 8A): S24–S28. 2003. View Article : Google Scholar
24	Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J and Cohn JS: Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 41:706–718. 2000.PubMed/NCBI
25	Barr SI, Kottke BA and Mao SJ: Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Am J Clin Nutr. 34:191–198. 1981.PubMed/NCBI
26	Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ and Garvey WT; DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 19:18–25. 2005. View Article : Google Scholar : PubMed/NCBI
27	Davidson M: A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 102:19L–27L. 2008. View Article : Google Scholar : PubMed/NCBI
28	Takemoto M and Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 21:1712–1719. 2001. View Article : Google Scholar : PubMed/NCBI
29	Dallongeville J, Fruchart JC, Maigret P, Bertolini S, Bon GB, Campbell MM, Farnier M, Langan J, Mahla G, Pauciullo P and Sirtori C: Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther. 3:103–110. 1998. View Article : Google Scholar
30	Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK and Durrington PN: Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin. Diabet Med. 28:100–108. 2011. View Article : Google Scholar : PubMed/NCBI
31	Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW and Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 53:766–772. 2007. View Article : Google Scholar : PubMed/NCBI